BYDUREON® exénatide
Bydureon® (suspension injectable d'exénatide à libération prolongée en stylo pré-rempli) est un agoniste du récepteur du glucagon-like peptide-1 (GLP-1), injectable une fois par semaine, présenté sous forme d'un stylo unidose, indiqué pour améliorer le contrôle glycémique chez les adultes atteints d'un diabète de type 2.
Références
- Henry RR, Klein EJ, Han J, Iqbal N. Efficacy and Tolerability of Exenatide Once Weekly Over 6 Years in Patients with Type 2 Diabetes: An Uncontrolled Open-Label Extension of the DURATION-1 Study. Diabetes Technol Ther. 2016;18(11):677-686.
- Diamant M, Van Gaal L, Guerci B, et al. Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial. Lancet Diabetes Endocrinol. 2014;2(6):464-473.
- Bydureon stylo, résumé des caractéristiques du produit, version la plus récente
- Données consignées, AstraZeneca Pharmaceuticals LP, 3211825. 2016.
- Drucker DJ, Buse JB, Taylor K, et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet. 2008;372(9645):1240-1250.
- Wysham CH, MacConell LA, Maggs DG, Zhou M, Griffin PS, Trautmann ME. Five-year efficacy and safety data of exenatide once weekly: long-term results from the DURATION-1 randomized clinical trial. Mayo Clin Proc. 2015;90(3):356-365.
- Buse JB, Drucker DJ, Taylor KL, et al. DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. Diabetes Care. 2010;33(6):1255-1261.
- Macconell L, Pencek R, Li Y, Maggs D, Porter L. Exenatide once weekly: sustained improvement in glycemic control and cardiometabolic measures through 3 years. Diabetes Metab Syndr Obes. 2013;6:31-41.
- LaRue S, Malloy J. Evaluation of the Dual-Chamber Pen Design for the Injection of Exenatide Once Weekly for the Treatment of Type 2 Diabetes. J Diabetes Sci Technol. 2015;9(4):815-821.
- Diamant M, Van GL, Stranks S, et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION 3): an open-label randomised trial. Lancet. 2010;375(9733):2234-2243.
- Hauber AB, Nguyen H, Posner J, Ervin C, LaRue S, Kalsekar I. Patient preferences for frequency of glucagon-like peptide-1 receptor agonist (GLP-1RA) injections in the treatment of type 2 diabetes. Poster présenté lors de : International Society for Pharmacoeconomics and Outcomes Research of the 19th Annual International Meeting; 31 mai-4 juin 2014 ; Montréal, Québec, Canada. Présentation de poster. 2016.
- DeYoung MB, Macconell L, Sarin V, Trautmann M, Herbert P. Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes. Diabetes Technol Ther. 2011;13(11):1145-1154.
- Blevins T, Pullman J, Malloy J, et al. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrin Metab. 2011;96(5):1301-1310.
- Buse JB, Nauck M, Forst T, et al. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet. 2013;381(9861):117-124.
- Trautman ME. Trautmann ME, Van Gaal L, Han J, Hardy E. Three-year efficacy and safety of exenatide once weekly: a pooled analysis of 3 trials. Poster présenté lors du : 51e congrès annuel de l'Association européenne pour l'étude du diabète ; 14 - 18 septembre 2015. Stockholm, Suède. Poster. 2016.
- Standards of Medical Care in Diabetes-2016. Diabetes Care. 2016;39(suppl 1):S1-S119. Diabetes Care. 2016.
- Résumé des caractéristiques du produit Lantus. 2015. 2016.
- Pistrosch et al. Pistrosch F, Köhler C, Schaper F, Landgraf W, Forst T, Hanefeld M. Effects of insulin glargine versus metformin on glycemic variability, microvascular and beta-cell function in early type 2 diabetes. Acta Diabetol. 2013;50(4):587-595. 2017.
- Données internes, AstraZeneca Pharmaceuticals LP, 3150204. 2016.
- Aronoff SL, Berkowitz K, Shreiner B, Want L. Glucose metabolism andregulation: beyond insulin and glucagon. Diabetes Spectrum. 2004;17(3):183-190. Diabetes Spectrum. 2016.
- Lim GE, Brubaker PL. Glucagon-like peptide 1 secretion by the L-cell: the view from within. Diabetes. 2006;55(suppl 2):S70-S77. Diabetes. 2016.
- Nielsen LL, Young AA, Parkes DG. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept. 2004;117(2):77-88.
- Astrazeneca Pharmaceuticals LP. Rapport d'évaluation périodique principale du rapport bénéfices-risques (20). 2016.Données internes, AstraZeneca Pharmaceuticals LP, 993604.011. 2016.
- ClinicalTrials.gov. Clinical Trials gov. https://clinicaltrials.gov/ct2/results?term=exenatide&Search=Search.
- US National Library of Medicine. National Institutes of Health. www ncbi nlm nih gov. http://www.ncbi.nlm.nih.gov/pmc/?term=exenatide. Consulté le 25 septembre 2015.
- Wysham CH, et al. Poster 1041-P. Presented at the American Diabetes Association’s 76th Scientific Sessions (ADA 2016), New Orleans, LA, June 40-14, 2016
- Klein EJ. Klein EJ, Henry RR, Malloy J, et al. DURATION-1 extension: efficacy and tolerability of exenatide once weekly over 6 years in patients with type 2 diabetes mellitus. Poster présenté lors du : 50e congrès annuel de l'Association européenne pour l'étude du diabète ; 15 - 19 août 2014 ; Vienne, Autriche. Poster. 2016.
- Johnston SS, Nguyen H, Felber E, et al. Retrospective study of adherence to glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes mellitus in the United States. Adv Ther. 2014;31(11):1119-1133.
- Monnier L, Colette C, Owens D. Postprandial and basal glucose in type 2 diabetes: assessment and respective impacts. Diabetes Technol Ther. 2011;13 Suppl 1:S25-S32.
- Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care. 2003;26(3):881-885.
- Riddle M, Umpierrez G, DiGenio A, Zhou R, Rosenstock J. Contributions of basal and postprandial hyperglycemia over a wide range of A1C levels before and after treatment intensification in type 2 diabetes. Diabetes Care. 2011;34(12):2508-2514.
- Giugliano D, Maiorino MI, Bellastella G, Chiodini P, Ceriello A, Esposito K. Efficacy of insulin analogs in achieving the hemoglobin A1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials. Diabetes Care. 2011;34(2):510-517.
- Vaag A, Lund SS. Insulin initiation in patients with type 2 diabetes mellitus: treatment guidelines, clinical evidence and patterns of use of basal vs premixed insulin analogues. Eur J Endocrinol. 2012;166(2):159-170.
- Bergenstal RM, Wysham C, Macconell L, et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION 2): a randomised trial. Lancet. 2010;376(9739):431-439.
- Diamant et al. Annexe complémentaire à : Diamant M, Van Gaal L, Guerci B, et al. Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial. Lancet Diabetes Endocrinol. 2014;2(6):1-12. Supplementary appendix. 2016.
- 3024913. Données internes, AstraZeneca Pharmaceuticals LP, 3024913. 2016.
- Données consignées. AstraZeneca Pharmaceuticals LP, 3123823. 2016.
NS ID BE-1052-RD05/2017-WEB Local code 660